 SAN DIEGO, Oct. 17, 2022 GLOBE NEWSWIRE -- Cidara Therapeutics, Inc. NASDAQ: CDTX, a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is presenting new clinical and preclinical data for rezafungin in six poster presentations at IDWeek taking place in-person in Washington, D.C. from October 19-23, 2022. The company will also participate in a pipeline symposium focused on new antimicrobials and ID diagnostics. 